GRAIL (GRAL) Expected to Announce Earnings on Thursday

GRAIL (NASDAQ:GRAL) will likely be posting its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect GRAIL to post earnings of ($3.33) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 20, 2026 at 4:00 PM ET.

GRAIL (NASDAQ:GRAL) last posted its earnings results on Wednesday, November 12th. The company reported ($2.46) EPS for the quarter, beating analysts’ consensus estimates of ($3.40) by $0.94. GRAIL had a negative net margin of 286.43% and a negative return on equity of 15.69%. The firm had revenue of $36.19 million for the quarter, compared to the consensus estimate of $33.83 million. On average, analysts expect GRAIL to post $-15 EPS for the current fiscal year and $-13 EPS for the next fiscal year.

GRAIL Price Performance

Shares of NASDAQ:GRAL opened at $100.40 on Thursday. GRAIL has a 12 month low of $20.44 and a 12 month high of $118.84. The firm has a market capitalization of $3.91 billion, a P/E ratio of -8.63 and a beta of 4.52. The company’s fifty day moving average price is $97.41 and its 200 day moving average price is $73.40.

Analysts Set New Price Targets

A number of research firms have recently commented on GRAL. Canaccord Genuity Group lifted their target price on GRAIL from $85.00 to $105.00 and gave the stock a “buy” rating in a research report on Monday, November 17th. Morgan Stanley lifted their price target on GRAIL from $85.00 to $110.00 and gave the stock an “equal weight” rating in a research report on Monday, December 1st. Guggenheim increased their price objective on GRAIL from $100.00 to $130.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $105.00.

Institutional Trading of GRAIL

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Comerica Bank increased its stake in shares of GRAIL by 59.2% during the third quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after acquiring an additional 173 shares during the period. NewEdge Advisors LLC boosted its holdings in GRAIL by 390.3% in the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock valued at $45,000 after purchasing an additional 1,401 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of GRAIL by 28.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after buying an additional 623 shares in the last quarter. CIBC Private Wealth Group LLC raised its stake in shares of GRAIL by 244.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,610 shares of the company’s stock worth $95,000 after buying an additional 1,142 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of GRAIL by 278.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,288 shares of the company’s stock valued at $118,000 after buying an additional 1,684 shares during the period.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.